Microplate Dx develops rapid antibiotic susceptibility testing diagnostic tests, enabling clinicians to confidently select the optimum antibiotic for a particular patients infection in less than 1 hour, significantly quicker than the current gold standard of days, reducing antimicrobial resistance and saving lives.
“The Microplate Dx team gained an ICURe NxNW award in July 2020 to be able to conduct focused market validation activities on their innovative rapid diagnostic test tackling antimicrobial resistance. Due to the Covid-19 pandemic, the majority of planned in person activities were moved online, however due to the time saved, the team were able to hold around 150 or so key conversations with major healthcare/pharmaceutical players in the antimicrobial resistance and wider diagnostics space. Several conversations led to follow on meetings post ICURe and we’re still partnering with some to this day for help around regulatory planning and clinical activities. During the programme, our market validation findings from such 150 conversations/activities were presented to a panel of experts who advised that most appropriate commercialisation strategy was to consider out-licensing the technology to a major player in the field. Despite this feedback, we went on to gain further spinout grant funding to continue de-risking our proposition, enabling the raise of a substantial pre-seed and subsequent seed investment rounds into Microplate Dx Limited less than 2 years later”
Dr Stuart Hannah, CEO Microplate Dx
£10k Longitude Prize Discovery Award
First patent GB1913035.0 Filing
£31k ICURe Programme Funding
£280k Scottish Enterprise Support (High Growth Spinout Programme)
£100k Royal Society of Edinburgh Enterprise Fellowship (Dr Stuart Hannah – CEO)
£360k private equity investment (Pre-Seed Round)
Microplate Dx spins out officially
£161k Scottish Enterprise R&D Grant
£2.5m private equity investment (Seed Round)
Microplate Dx’s long term vision is to be the vanguard for tackling the global antimicrobial resistance threat. Our mission is to accelerate treatment decisions and improve patient quality of life, through pioneering antimicrobial stewardship-enabling diagnostics. We established in early 2022 with the overarching aim to safeguard against the spread of antimicrobial resistance around the world.
Microplate Dx is developing a revolutionary diagnostic technology to tackle drug-resistant infections head on, ensuring patients get the right antibiotic treatment straightway. Our team is currently developing our first product focused on tackling urinary tract infections (UTIs), but in future, our platform will be extended into other key areas of need for example sepsis and fungal infections.